REFERENCES
1. Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol 2017;13:509-20.
2. Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocrine Reviews 2019;40:1367-93.
3. Stefan N, Schick F, Birkenfeld AL, Häring HU, White MF. The role of hepatokines in NAFLD. Cell Metab 2023;35:236-52.
5. Song WJ, Mondal P, Wolfe A, et al. Glucagon regulates hepatic kisspeptin to impair insulin secretion. Cell Metab 2014;19:667-81.
6. Meex RC, Hoy AJ, Morris A, et al. Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism. Cell Metab 2015;22:1078-89.
7. El Ouaamari A, Dirice E, Gedeon N, et al. SerpinB1 promotes pancreatic β cell proliferation. Cell Metab 2016;23:194-205.
8. Tao R, Wang C, Stöhr O, et al. Inactivating hepatic follistatin alleviates hyperglycemia. Nat Med 2018;24:1058-69.
9. Gong XM, Li YF, Luo J, et al. Gpnmb secreted from liver promotes lipogenesis in white adipose tissue and aggravates obesity and insulin resistance. Nat Metab 2019;1:570-83.
10. Wang Q, Sharma VP, Shen H, et al. The hepatokine Tsukushi gates energy expenditure via brown fat sympathetic innervation. Nat Metab 2019;1:251-60.
11. Montgomery MK, Bayliss J, Devereux C, et al. SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control. Sci Transl Med 2020;12:eaaz8048.
12. Zhou B, Luo Y, Ji N, Hu C, Lu Y. Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis. Nat Metab 2022;4:1185-201.
